Business
'엑스탄디', 비전이성 호르몬 민감성 전립선암 치료제로 EU 승인 - 헬스조선
占싣쏙옙占쌘띰옙占쏙옙占쏙옙占쏙옙 占쏙옙占쏙옙占쏙옙탄占쏙옙(占쏙옙占싻몌옙 占쏙옙占쌩뤄옙타占쏙옙占싱듸옙)占쏙옙占쏙옙 占쏙옙占쏙옙占싱쇽옙 호占쏙옙占쏙옙 占싸곤옙占쏙옙 占쏙옙占쏙옙占쏙옙占쏙옙 치占쏙옙占쏙옙占쏙옙 占쏙옙占쏙옙...
By: Chosun.com
- Apr 26 2024
- 0
- 0 Views
( ) (EU) . (mHSPC) (CRPC) 3 .EU 23() , ?BCR) (nmHSPC) ?. ? (ADT) . ? ? , (nmCRPC) .
? ( ? 3 ? ?57.6% . ? ? ?36.9% . ? ? ? ? ? .
? , ?? 20~40% 10 ?. ? 90% ? .